Pays: États-Unis
Langue: anglais
Source: NLM (National Library of Medicine)
FLUMAZENIL (UNII: 40P7XK9392) (FLUMAZENIL - UNII:40P7XK9392)
Physicians Total Care, Inc.
FLUMAZENIL
FLUMAZENIL 0.1 mg in 1 mL
INTRAVENOUS
PRESCRIPTION DRUG
Flumazenil is indicated for the complete or partial reversal of the sedative effects of benzodiazepines in cases where general anesthesia has been induced and/or maintained with benzodiazepines, where sedation has been produced with benzodiazepines for diagnostic and therapeutic procedures, and for the management of benzodiazepine overdose. Flumazenil is indicated for the reversal of conscious sedation induced with benzodiazepines. (See PRECAUTIONS–Pediatric Use .) Flumazenil is contraindicated: - in patients with a known hypersensitivity to flumazenil or benzodiazepines. - in patients who have been given a benzodiazepine for control of a potentially life-threatening condition (eg, control of intracranial pressure or status epilepticus). - in patients who are showing signs of serious cyclic antidepressant overdose. (See WARNINGS .) Flumazenil acts as a benzodiazepine antagonist, blocks the effects of benzodiazepines in animals and man, antagonizes benzodiazepine reinforcement in animal models, produces dyspho
Flumazenil injection is supplied as follows: Store at 20°-25° C (68°-77° F) [see USP Controlled Room Temperature]
Abbreviated New Drug Application
FLUMAZENIL - FLUMAZENIL INJECTION PHYSICIANS TOTAL CARE, INC. ---------- FLUMAZENIL INJECTION PACKAGE INSERT RX ONLY DESCRIPTION Flumazenil injection is a benzodiazepine receptor antagonist. Chemically, flumazenil is ethyl 8-fluoro- 5,6-dihydro-5-methyl-6-oxo-4H-imidazo [1,5-a](1,4) benzodiazepine-3-carboxylate. Flumazenil has an imidazobenzodiazepine structure, a calculated molecular weight of 303.3, and the following structural formula: Flumazenil is a white to off-white crystalline compound with an octanol: buffer partition coefficient of 14 to 1 at pH 7.4. It is insoluble in water but slightly soluble in acidic aqueous solutions. Flumazenil is available as a sterile parenteral dosage form for intravenous administration. Each mL contains 0.1 mg of flumazenil compounded with 1.8 mg of methylparaben, 0.2 mg of propylparaben, 0.9% sodium chloride, 0.01% edetate disodium, and 0.01% acetic acid; the pH is adjusted to approximately 4 with hydrochloric acid and/or, if necessary, sodium hydroxide. CLINICAL PHARMACOLOGY Flumazenil, an imidazobenzodiazepine derivative, antagonizes the actions of benzodiazepines on the central nervous system. Flumazenil competitively inhibits the activity at the benzodiazepine recognition site on the GABA/benzodiazepine receptor complex. Flumazenil is a weak partial agonist in some animal models of activity, but has little or no agonist activity in man. Flumazenil does not antagonize the central nervous system effects of drugs affecting GABA-ergic neurons by means other than the benzodiazepine receptor (including ethanol, barbiturates, or general anesthetics) and does not reverse the effects of opioids. In animals pretreated with high doses of benzodiazepines over several weeks, flumazenil elicited symptoms of benzodiazepine withdrawal, including seizures. A similar effect was seen in adult human subjects. PHARMACODYNAMICS Intravenous flumazenil has been shown to antagonize sedation, impairment of recall, psychomotor impairment and ventilatory depression produced by benzodiazepines in he Lire le document complet